GDRX Stock Recent News

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) (“GoodRx” or the “Company”), the leading platform for medication savings in the U.S., today announced it will release its second quarter 2025 financial results after U.S. markets close on Wednesday, August 6, 2025. GoodRx management will also hold a conference call and webcast the following morning, Thursday, August 7, 2025 at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company's busin.

Investors with an interest in Medical Services stocks have likely encountered both GoodRx Holdings, Inc. (GDRX) and HealthEquity (HQY). But which of these two stocks is more attractive to value investors?

GoodRx connects uninsured and underinsured consumers with prescription discounts, acting as a broker between consumers, PBMs, and pharmacies. Recent OBBBA legislation will significantly cut Medicaid spending, leaving millions more Americans uninsured or underinsured over the next decade. GoodRx stands to benefit as its platform becomes increasingly relevant for the growing population losing Medicaid coverage and seeking affordable prescriptions.

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced the launch of a new subscription service for erectile dysfunction (ED). Designed to meet consumers where they are and remove common barriers such as high costs, long wait times, and inconvenience, this all-in-one solution offers a fast, discreet, and affordable option for ED treatment. A new report from GoodRx reveals a clear gap in care: nearly 1 in 3 U.S. men.

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced the launch of GoodRx Community Link. Designed to address the industry challenges that independent community pharmacies face around complex reimbursement models and competitive pressures, Community Link leverages a cost-plus pricing model based on NADAC to provide predictable pricing and favorable economics. This announcement showcases GoodRx's commitment to help.

I'm reiterating my Buy rating on GoodRx, as its valuation is compelling and the business is showing signs of stabilization under new leadership. GoodRx's recurring revenue base, expanding pharma partnerships, and robust EBITDA margins support the investment thesis for a rebound. Despite risks like Rite Aid's bankruptcy and flat consumer growth, GoodRx's direct pharma channel is growing double digits and offsetting headwinds.

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced that it will launch a new offering for independent community pharmacies - GoodRx Community Link - in June 2025. GoodRx Community Link will enable locally owned and operated pharmacies to directly contract with GoodRx on pricing and manage participation in the company's Integrated Savings Programs (ISP). Direct contracts leverage cost-plus models to provide indep.

JP Morgan analyst Lisa C. Gill revised her 2025 outlook on GoodRx Holdings GDRX following the company's first-quarter earnings.

Five Health and Fitness stocks to buy now are: SFM, DXCM, HIMS, UNFI, GDRX.

Investors looking for stocks in the Medical Services sector might want to consider either GoodRx Holdings, Inc. (GDRX) or Progyny (PGNY). But which of these two stocks is more attractive to value investors?